BioXcel Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of BioXcel Therapeutics generated cash of -$155,006,000, which is less than the previous year. Cash used in financing activities reached the amount of $26,522,000 last year. Net change in cash is therefore -$128,504,000.
Cash Flow
| 2015 | -280K | -1K | 281K |
|---|---|---|---|
| 2016 | -1.29M | -4K | 1.29M |
| 2017 | -2.19M | 0 | 3.08M |
| 2018 | -13.50M | -340K | 55.52M |
| 2019 | -27.28M | -870K | 18.01M |
| 2020 | -66.35M | -316K | 247.35M |
| 2021 | -82.15M | -445K | 102.44M |
| 2022 | -135.34M | -139K | 96.23M |
| 2023 | -155.00M | -20K | 26.52M |
BTAI Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 193.72M | 232.96M | 213.11M | 32.42M | 42.56M | 887K | 0 | 0 | 0 |
Operating activities | |||||||||
Net income | -179.05M | -165.75M | -106.93M | -82.16M | -32.96M | -19.27M | -4.53M | -2.12M | -636K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 318K | 327K | 297K | 188K | 156K | 17K | 1K | 0 | 0 |
Stock-based compensation expense | 18.61M | 17.33M | 19.45M | 14.61M | 3.14M | 0 | 1.60M | 671K | 0 |
| Deferred income tax benefit | 18.61M | 17.33M | 19.45M | 14.61M | 3.14M | 0 | 1.60M | 671K | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 177K | -248K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -6K | -1.98M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -3.21M | 13.03M | 4.85M | 3.03M | 3.58M | 3.20M | 737K | 156K | 0 |
Cash generated by operating activities | -155.00M | -135.34M | -82.15M | -66.35M | -27.28M | -13.50M | -2.19M | -1.29M | -280K |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -20K | -139K | -445K | -316K | -870K | -340K | 0 | -4K | -1K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -20K | -139K | -445K | -316K | -870K | -340K | 0 | -4K | -1K |
Financing activities | |||||||||
Common Stock Issued | 27.03M | 3 | 102.44M | 256.38M | 17.81M | 56.51M | 2.06M | 0 | 281K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -9.02M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 98.6M | 0 | 0 | 0 | -371K | 438K | 0 | 0 |
Cash used in financing activities | 26.52M | 96.23M | 102.44M | 247.35M | 18.01M | 55.52M | 3.08M | 1.29M | 281K |
Net Change In Cash | -128.50M | -39.24M | 19.84M | 180.69M | -10.13M | 41.67M | 887K | 0 | 0 |
Cash at end of period | 65.22M | 193.72M | 232.96M | 213.11M | 32.42M | 42.56M | 887K | 0 | 0 |
| Data source | Data source | Data source | Data source | Data source | Data source |